



**BEST AVAILABLE COPY**

Dkt. 0179/61248-A/JPW/BJA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Gregory B. Wilson and R. Riley Shuler  
U.S. Serial No.: 09/776,010 Examiner: Bao Qun Li  
Filed : February 2, 2001 Group Art Unit: 1648  
For : HUMAN HERPESVIRUS 6A AND 6B TRANSFER FACTORS  
FOR THE TREATMENT OF CHRONIC FATIGUE  
SYNDROME AND MULTIPLE SCLEROSIS

1185 Avenue of the Americas  
New York, New York 10036

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**DECLARATION OF GREGORY B. WILSON UNDER 37 C.F.R. §1.132**

I, Gregory B. Wilson, hereby declare as follows:

1. I am a coinventor of the subject matter claimed in the above-identified patent application.
2. I have experience in the production and study of transfer factors (the "art") and I have authored peer-reviewed publications relating to transfer factors. A copy of my curriculum vitae is attached hereto as **Exhibit A**.
3. I understand that pending claims 32-40, 42, 43, 46 and 47 as amended in the accompanying Amendment provide (i) a fluid consisting of a colostrum of a human herpesvirus-6A-immunized lactating bovid or of a herpesvirus-6B-immunized lactating bovid, wherein the colostrum has removed from it cells, casein and fat, (ii) related lyophilates and pharmaceutical compositions, and (iii) related methods of treating chronic fatigue syndrome. I am also familiar with the level of skill in the art as of February 2, 2000, the priority date of the subject application (the "priority date").

Applicants: Gregory B. Wilson et al.  
Serial No.: 09/776,010  
Filed: February 2, 2001  
Page 2

4. I have read the January 11, 2005 Office Action and July 13, 2005 Advisory Action which were issued by the U.S. Patent and Trademark Office in connection with the subject application.
5. I understand that in the January 11, 2005 Office Action, the Examiner assigned to the subject application rejected claims 32-40, 42, 43, 46 and 47 as allegedly anticipated by an advertisement by Chisolm Biological Laboratory ("Chisolm") on page 29 of Positive Health News, report No. 17, Fall Issue (1998) (the "1998 advertisement", annexed as **Exhibit B**), in view of an advertisement by Chisolm on page 27 of Positive Health News, Fall Issue (1997) (the "1997 advertisement", annexed as **Exhibit C**). I also understand that the Examiner has maintained this rejection in the July 13, 2005 Advisory Action. In support of this rejection, I understand the Examiner to assert the following: (i) the 1998 advertisement teaches, in relevant part, a product which (a) comprises an "antigen-specific transfer factor (TF) with an immunological stimulatory function" and (b) is "specific against particular antigen(s), including HHV6", and (ii) the 1997 advertisement teaches, in relevant part, that the "Immunfactor [of Chisolm] is a colostrums product."
6. It is my opinion that, as of the priority date, based on the 1998 advertisement in view of the 1997 advertisement, and absent undue experimentation, one skilled in the art could not have made a fluid consisting of a colostrum of a human herpesvirus-6A-immunized lactating bovid or of a herpesvirus-6B-immunized lactating bovid, wherein the colostrum has removed from it cells, casein and fat. My opinion is based on the following points.

7. With regard to the Examiner's assertion that the 1998 advertisement teaches a product which (a) comprises an "antigen-specific transfer factor (TF) with an immunological stimulatory function" and (b) is "specific against particular antigen(s), including HHV6", I note that the advertisement does not teach this product to be a colostrum product, wherein colostrum is derived from an immunized lactating bovid and has removed from it cells, casein and fat.
8. With regard to the Examiner's assertion that the 1997 advertisement teaches the "Immunfactor [of Chisolm] is a colostrums product", I note that the 1997 advertisement (i) states that one should "not be fooled by simple dried colostrums/whey products (already marketed for years) which elicit a nonspecific immune response", yet (ii) does not indicate the source of the products offered in the 1997 advertisement.
9. It is also my opinion that when taken in view of the 1997 advertisement, the 1998 advertisement, as of the priority date, would not have taught one skilled in the art, inter alia, the steps of immunizing a bovid with human herpesvirus 6A or 6B, collecting the resulting colostrum of the lactating bovid, and removing cells, casein and fat, leading to the claimed fluids and related compositions and methods.
10. In summary, it is my opinion that as of the priority date, one skilled in the art would not have been able to make the claimed fluids and related compositions or practice the related methods based on the 1998 advertisement in view of the 1997 advertisement.

02/14/2006

21:07

FURMAN DEVELOPMENT DEPARTMENT → 82123910526##566748

NO.818

W02

Feb-13-06

07:36am

From: Cooper & Dunham LLP

+212 381 0329

( 7-222 P 307/033 P-582

Applicants: Gregory B. Wilson et al.  
Serial No.: 09/776,010  
Filed: February 2, 2006  
Page 4

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that any such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signed:

Gregory B. Wilson, Ph.D.

Date:

2/13/06

## **RESUME OF QUALIFICATIONS**

**Greg B. Wilson**

### **EDUCATION**

**CERTIFIED TO TEACH GIFTED AND TALENTED (2002)**

**AP BIOLOGY AND AP CHEMISTRY CERTIFIED (1998)**

**CRITICAL NEED TEACHER CERTIFICATION PROGRAM (1995)**

**Administered by Winthrop University, Rock Hill, SC.**

**Secondary Teaching Certificate Number: 169290 ( Code-12, Science)**

**THIRTY SEMESTER HOURS TOWARDS M.S. DEGREE IN CHEMISTRY**

**Clemson University, Clemson , SC**

**Attended: 8/89 to 7/90**

**M.A. DEGREE IN BUSINESS ADMINISTRATION (1988)**

**Webster University, St. Louis, MO (Charleston, SC campus)**

**Ph.D. DEGREE IN BIOLOGY (1974)**

**University of California at Los Angeles**

**Specialized in Cell Biology, Microbiology and Immunology**

**B.A. DEGREE IN ZOOLOGY (1971)**

**University of California at Los Angeles**

**Specialized in Cell Physiology and Chemistry**

### **ACADEMIC EXPERIENCE**

#### **PROFESSOR**

**(1999)**

**Clemson University**

**Department of Animal and Veterinary Science**

**Duties: Research and Liaison between Animune Inc., and Clemson University**

#### **SCIENCE TEACHER**

**8/96 to present**

**J. L. Mann High School, Academy of Mathematics, Science and Technology**

**Department of Science, Greenville, SC 29607**

**Duties: Teaching and Student Advising**

**Courses Taught:**

**-A. P. Biology**

**-Anatomy and Physiology**

**-C. P. Biology, Biology Honors, Tech-Prep Biology**

**-Genetics (started course)**

**-Microbiology (started course)**

**-CP and Tech-Prep Chemistry, AP Chemistry**

**-Marine Science**

**INSTRUCTOR (Part-time Appointment)** 5/94 to 7/96  
**Florence-Darlington Technical College**  
Department of Natural Sciences, Florence, SC 29501  
**Courses Taught:** Biology 210 & 211 (Anatomy & Physiology)

**SCIENCE TEACHER** 8/92 to 6/96  
**West Florence High School**  
Department of Science, Florence, SC 29501  
**Duties:** Teaching, Student Guidance/Advising, Science Club, Academic Team  
**Courses Taught:**  
- Biology  
- Physical Science  
- Genetics (started course)

**AWARDS, GRANTS and OTHER ACCOMPLISHMENTS:**  
-APTS Mini-Grant Award (1995) to establish science elective course in genetics.

**ASSOCIATE PROFESSOR OF CHEMISTRY** 8/91 to 12/92  
**Francis Marion University**  
Department of Chemistry and Physics, Florence, SC 29501  
**Duties:** Teaching, Student Guidance/Advising  
**Courses Taught:**  
- Physical Science 101  
- Chemistry 101 & 102 (General Chemistry, Laboratory Only)  
- Chemistry 201 & 202 (Organic Chemistry, Laboratory Only)

**AWARDS, GRANTS and OTHER ACCOMPLISHMENTS:**  
- Dwight D. Eisenhower Grant Award (1992: Commission of Higher Education) for "Pee Dee Regional Science Enrichment Program for Economically Disadvantaged Middle School Students"  
- Co-Director of Pee Dee Science Enrichment Program (1992)  
- Board of Directors, SC Region IV Middle /Elementary School Academy of Sciences (1992)

**ASSISTANT PROFESSOR OF CHEMISTRY AND BIOLOGY** 8/90 to 7/91  
**University of Kentucky at Hazard Community College**  
Division of Sciences and Related Technologies, Hazard, KY 41701  
**Duties:** Teaching, Student Guidance/Advising, Community Service, Institutional Committees and Professional Development  
**Courses Taught:**  
- Biology 103 (General Biology)  
- Chemistry 104 (Introductory General, Organic & Biochemistry)  
- Chemistry 105, 107 & 115 (General College Chemistry)  
- Chemistry 230 & 231 (Organic Chemistry)

**INSTRUCTOR (Summer Appointment)** Summer II, 1990  
**Anderson College**  
Department of Chemistry, Anderson, SC 29621  
**Courses Taught:** Chemistry 202 (Organic Chemistry II, Lecture Only)

**GRADUATE TEACHING ASSISTANT** 8/89 to 8/90  
**Clemson University**  
Department of Chemistry, Clemson, SC 29634

Courses Taught:

- Chemistry 101 & 102 (General Chemistry, Laboratory Only)
- Chemistry 227 ( Microlaboratory Methods in Organic Chemistry)

INSTRUCTOR (Summer Appointment)

Summer II, 1989

Spartanburg Methodist College

Division of Math and Science, Spartanburg, SC 29301

Courses Taught: Chemistry 202 (Organic Chemistry I)

INSTRUCTOR (Summer Appointment)

Summer I B, 1989

University of South Carolina at Sumter

Division of Math, Science, and Engineering, Sumter, SC 29150

Courses Taught: Biology 232 (Anatomy & Physiology)

INSTRUCTOR (Part-time Appointment)

3/89 to 5/89

Trident Technical College

Department of Biological Sciences, Charleston, SC 29411

Courses Taught: Biology 141 (Microbiology)

VARIOUS FACULTY POSITIONS

11/75 to 6/98

Medical University of South Carolina (MUSC)

Departments of Microbiology and Immunology and Pediatrics

Charleston, SC 29425

(Held faculty positions of progressively increasing rank; highest ranks shown)

Adjunct Associate Professor (1987 to 1998)

Department of Microbiology and Immunology

Colleges of Medicine and Dental Medicine

Associate Professor (1982 to 1987)

Department of Pediatrics

College of Medicine

Associate Professor (1979 to 1987)

Department of Microbiology and Immunology

Colleges of Medicine and Dental Medicine

Courses Taught:

- Basic and Clinical Microbiology for Pharmacy and Allied Health Students (1983 to 1984)
- Medical Microbiology and Immunology (1976 to 1979; 1982 and 1983)
- Molecular and Cellular Biology and Pathobiology (1980 to 1984)
- Cellular Immunology (1978 and 1979)
- Immunochemistry (1976 to 1978)

Departmental and University-Wide Committees:

- Graduate Education Committee (1978 and 1979)
- Curriculum Committee, College of Graduate Studies (1982 to 1986)
- Institutional Committee for the Care and Use of Animals (1982 to 1986)
- Long Range Planning and Development Committee (1984 and 1985)
- Departmental Graduate Committee (1978 and 1979)
- Departmental Patent Committee (1980)
- Research Committee for Evaluation of University Applications for State Research Support (1979 and 1982)

- Research Committee for Selection of Students for Summer Research Assistantships (1979)

Listed (Academic Accomplishments and Community Service):

- Personalities of the South (1979 and 1980)
- Who's Who in the South and Southwest (1980 to 1984)
- Men of Achievement (1981)
- The Directory of Distinguished Americans (1981)
- Personalities of America (1982)
- International Who's Who of Intellectuals (1981)
- Community Leaders of America (1982)
- American Men and Women of Science (1982)
- Outstanding Young Men of America (1982)
- Who's Who in Frontier Science and Technology (1984 and 1985)
- Community Leaders of the World (1983 and 1984)
- Who's Who Directory of Professionals and Resources in Cancer ( 1984 and 1985)
- Who's Who in the World (1984 and 1985)

Awards, Grants and Other Accomplishments:

- Granted Tenure (1980)
- Preceptor, Summer Health Careers Program, Office of Minority Affairs, MUSC Extension Programs (every summer, 1978 to 1982)
- Research Fellow, National Cystic Fibrosis Foundation (1974 to 1976)
- Basil O'Conner grant award, National Foundation March of Dimes (1976 to 1979)
- Awarded several other intramural or private foundation grants to support research programs (1976 to 1983)
- Published over 80 papers, reviews or books (1973 to 1984)
- Obtained two United States patents for inventions which stemmed from applicants research

**PAST MEMBERSHIPS**

- South Carolina Science Council
- South Carolina Education Association
- National Education Association
- National Science Teachers Association



## **BUSINESS EXPERIENCE**

### **BioLogics Inc.**

1997 to present

412 Beckenham Lane, Greenville, SC 29609

Firm involved in consulting and diagnostic testing for the development and marketing of products for the immune system.

President, CEO, and Chairman of the Board: (1997 to present)

### **Animune Inc.**

1993 to present

1118 Putter Path N. W., Orangeburg, SC 29115

Firm involved in the development, manufacturing, and marketing of biological products for human and animal health.

Member, Board of Directors: (1993 to present)

Vice President and COO of the Greenville Nutritional Products Manufacturing Facility: 1998-present

#### **Business Accomplishments:**

- Designed and supervised the construction of a licensed facility for the manufacturing of nutritional products for the immune system.

### **Amtron Inc.**

1981 to 1989

701 East Bay Street, Charleston, SC 29403

USDA licensed firm involved in the development, manufacturing, and marketing of biological products for animal and human health. Directed research and product development efforts while on a sabbatical and leave of absence from MUSC.

Senior Scientific Consultant: (10/88 to 12/89)

Vice President, Research, Product Development and Testing: (6/84 to 10/88)

Consultant: (9/81 to 6/84)

Member, Board of Directors: (1981 to 1989)

#### **Business Accomplishments:**

- Designed and supervised the construction of a 6000 square foot pilot plant with facilities for manufacturing animal biologics and for research and product development (1984). Obtained USDA Establishment License in conjunction with first product license (1988).
- Designed and supervised the construction of a 20 acre clinical testing / research farm (1986). Obtained approval from state DHEC (1986) and USDA (1988).
- Developed contracts, protocols, and administratively managed a cooperative of up to 10 dairy farms in South Carolina to provide sources of raw materials for Amtron's "Specific Immunity Inducer" product line (1984 to 1988).
- Obtained and managed 14 different grants and contracts which provided over \$ 4 million in funding for Amtron's operations and scientific programs (1984 to 1988). Included first Small Business Innovation Phase I and Phase II NIH grants awarded to a business in South Carolina (1984 and 1987).
- Established and administratively managed contractual relationships and sponsored research programs at the USDA-ARS (Beltsville, MD), MUSC, North Carolina State University, Iowa State University, University of Virginia, University of Illinois, University of Arkansas, University of Georgia, and other institutions to facilitate the advancement of Amtron's scientific programs (1984 to 1988).

**Greg B. Wilson**  
**Page six**

- Coordinated research, development and clinical testing programs which led to the development of over 30 experimental products for the prevention of infectious diseases of either swine, poultry, equine, canine or bovine (1984 to 1988).
  - Obtained first product license issued for an immunomodulator by the USDA (Swine Transmissible Gastroenteritis Immunity Inducer, Product Code: 9691.00; USDA-APHIS, March, 1988).
  - Obtained United States and foreign patents to protect Amtron's products.
  - Published six papers reporting results pertaining to Amtron's products.
-

## PUBLICATIONS

(Abstracts Not Included)

### Papers

1. G.B. Wilson, T.L. Jahn, and J.R. Fonseca. Demonstration of serum protein differences in cystic fibrosis by isoelectric focusing in thin layer polyacrylamide gels. Clin. Chim. Acta 49: 79-91, 1973.
2. G.B. Wilson and T.L. Jahn. Decreased rate of cytolysis of Colpidium striatum by cystic fibrosis serum. I. Bioassay and evidence for the possible involvement of a CF factor - IgG complex. Life Sciences 15:551-567, 1974.
3. G.B. Wilson, T.L. Jahn, and J.R. Fonseca. Helical nature of the ciliary beat of Colpidium striatum. Acta Protozool. 13: 383-395, 1975.
4. G.B. Wilson, T.L. Jahn, and J.R. Fonseca. Studies on ciliary beating of frog pharyngeal epithelium in vitro. I. Isolation and ciliary beat of single cells. Trans. Amer. Micros. Soc. 94: 43-57, 1975.
5. G.B. Wilson, T.L. Jahn, P.J. Quinton, and J.R. Fonseca. Studies on ciliary beating of frog pharyngeal epithelium in vitro. II. Relationship between beat form, metachronal coordination, fluid flow and particle transport. In: Swimming and Flying in Nature, Vol. I (T.Y. -T. Wu, C.J. Brokaw, C. Brennen eds.), Plenum Pub. Co, N.Y., pp. 301-316, 1975.
6. G.B. Wilson, H.H. Fudenberg, and T.L. Jahn. Studies on cystic fibrosis using isoelectric focusing. I. An assay for detection of cystic fibrosis homozygotes and heterozygote carriers from serum. Pediat. Res. 9: 635-640, 1975.
7. G.B. Wilson and H.H. Fudenberg. Studies on cystic fibrosis using isoelectric focusing. II. Demonstration of deficient proteolytic cleavage of alpha-2-macroglobulin in cystic fibrosis plasma. Pediat. Res. 10: 87-96, 1976.
8. G.B. Wilson and H.H. Fudenberg. Further purification and characterization of serum proteins used to detect cystic fibrosis genotypes by isoelectric focusing. Tex. Rep. Biol. Med. 34: 51-71, 1976.
9. G.B. Wilson, T.M. Welch, and H.H. Fudenberg. Human transfer factor in guinea pigs: Partial purification of the active component. In: Transfer Factor: Basic Properties and Clinical Applications (M.S. Ascher, A.A. Gottlieb, C.H. Kirkpatrick, eds.) Academic Press, pp. 409-424, 1976.

- (10.) I.M. Welch, G.B. Wilson, and H.H. Fudenberg. Human transfer factor in guinea pigs: Further studies. In: Transfer Factor: Basic Properties and Clinical Applications (M.S. Ascher, A.A. Gottlieb, C.H. Kirkpatrick, eds.) Academic Press, pp. 399-408, 1976.
11. G.B. Wilson, N.M. Burdash, P. Arnaud, M.T. Monsher, and H.H. Fudenberg. Carcinoembryonic antigen and cystic fibrosis protein in blood from cystic fibrosis homozygotes and heterozygote carriers. Scand. J. Immunol. 5: 829-836, 1976.
12. G.B. Wilson, P. Arnaud, M.T. Monsher, and H.H. Fudenberg. Detection of cystic fibrosis protein by electrofocusing. Pediat. Res. 10: 1001-1002, 1976.
13. P. Arnaud, C. Chapuis-Cellier, G. Souillet, R. Carron, G.B. Wilson, R. Creyssel, and H.H. Fudenberg. High frequency of deficient Pi phenotypes of alpha-1-antitrypsin in nonatopic infantile asthma. Trans. Ass. Amer. Phys. 89: 205-214, 1976.
14. P. Arnaud, N.M. Burdash, G.B. Wilson, and H.H. Fudenberg. Alpha-1-antitrypsin (Pi) types in Down's syndrome. Clin. Genet. 10: 239-243, 1976.
- (15) G.B. Wilson, T.M. Welch, and H.H. Fudenberg. Tx: A component in human dialyzable transfer factor that induces delayed hypersensitivity in guinea pigs. Clin. Immunol. Immunopathol. 7: 189-207, 1977.
16. G.B. Wilson, M.T. Monsher, and H.H. Fudenberg. Additional notes on the use of analytical isoelectric focusing for the detection of cystic fibrosis protein in serum. Pediat. Res. 11: 139-141, 1977.
17. G.B. Wilson, M.T. Monsher, and H.H. Fudenberg. Studies on cystic fibrosis using isoelectric focusing. III. Correlation between cystic fibrosis protein and ciliary dyskinesia activity in whole serum shown by a modified rabbit tracheal bioassay. Pediat. Res. 11: 143-145, 1977.
18. G.B. Wilson, M.T. Monsher, P. Arnaud, and H.H. Fudenberg. Diagnosis of cystic fibrosis (CF)-purification and distinction between CF protein and ciliary dyskinesia activity in CF and asthmatic sera using isoelectric focusing and the rabbit tracheal ciliary bioassay. In: Electrofocusing and Isotachopheresis (B. J. Radola and D. Graesslin, eds.) Walter de Gruyter, Berlin-New York, pp. 337-350, 1977.
19. P. Arnaud, C. Chapuis-Cellier, G.B. Wilson, J. Koistinen, R.C. Allen, and H.H. Fudenberg. Polyacrylamide gel isoelectric focusing applied to alpha-1-proteinase inhibitor phenotyping. II. Immunochemical procedures. In: Electrofocusing and Isotachopheresis (B. J. Radola and D. Graesslin, eds.) Walter de Gruyter, Berlin-New York, pp. 265-272, 1977.

20. G.B. Wilson and H.H. Fudenberg. Studies on cystic fibrosis using isoelectric focusing. IV. Distinction between ciliary dyskinesia activity in cystic fibrosis and asthmatic sera and association of CF protein with the activity in CF serum. Pediat. Res. 11: 317-324, 1977.
21. G.B. Wilson, P. Arnaud, and H. H. Fudenberg. An improved method for the detection of cystic fibrosis protein in serum using the LKB Multiphor electrofocusing apparatus. Pediat. Res. 11: 986-989, 1977.
22. G.B. Wilson and H.H. Fudenberg. Ciliary dyskinesia factors in cystic fibrosis and asthma. Nature 266: 463-464, 1977.
23. P. Arnaud, J. Koistinen, G.B. Wilson, and H.H. Fudenberg. Alpha-1-antitrypsin (Pi) phenotypes in a Finnish population. Scand. J. Lab. Clin. Med. 37: 339-343, 1977.
24. G.B. Wilson, T.M. Welch, D.R. Knapp, A. Horsmanheimo, and H.H. Fudenberg. Characterization of the components in Tx -- an active subfraction of human dialyzable transfer factor. I. Identification of the major component in TFg, a precursor of Tx, as hypoxanthine. Clin. Immunol. Immunopathol. 8: 551-569, 1977.
25. P. Arnaud, G.B. Wilson, J. Koistinen, and H.H. Fudenberg. Immunofixation after electrofocusing: Improved method for specific detection of serum proteins with determination of isoelectric points. I. Immunofixation print technique for detection of alpha-1-proteinase inhibitor. J. Immunol. Methods 16: 221-231, 1977.
26. G.B. Wilson and H.H. Fudenberg. Role of polyamines in regulation of proteinase and proteinase inhibitor function: Emphasis on a defect in alpha-2-macroglobulin and polyamine metabolism in cystic fibrosis. In: Advances in Polyamine Research, Volume 2 (R.A. Campbell, D.R. Morris, D. Bartos, G.D. Daves, F. Bartos et al., eds.). Raven Press, New York, pp. 281-305, 1978.
27. G.B. Wilson and H.H. Fudenberg. Is cystic fibrosis protein a diagnostic marker for individuals who harbor the defective gene? Pediat. Res. 12: 801-804, 1978.
28. G.B. Wilson, H.H. Fudenberg, and V.J. Bahm. Distinct components in dialyzable leukocyte extracts have specific and nonspecific effects on cellular immunity as shown by leukocyte migration inhibition. Trans. Assoc. Amer. Phys. 91: 294-332, 1978.
29. G.B. Wilson and H.H. Fudenberg. Separation of ciliary dyskinesia substances secreted by cystic fibrosis leukocytes, lymphoid cell lines and found in serum, using Protein A Sepharose CL-4B. J. Lab. Clin. Med. 92: 463-482, 1978.

30. G.B. Wilson, H.H. Fudenberg, and M. Horsmanheimo. Effects of dialyzable leukocyte extracts with transfer factor activity on leukocyte migration in vitro. I. Antigen-dependent inhibition and antigen-independent inhibition and enhancement of migration. J. Lab. Clin. Med. 93: 800-818, 1979.
31. G.B. Wilson and H.H. Fudenberg. Effects of dialyzable leukocyte extracts (DLE) with transfer factor activity on leukocyte migration in vitro. II. Separation and partial characterization of the components in DLE producing antigen dependent and independent effects. J. Lab. Clin. Med. 93: 819-837, 1979.
32. R.T. Newell, G.B. Wilson, L. Reddick, N.M. Burdash, H.H. Fudenberg, V.J. Bahm, and P.H. Klesius. In-vitro effects of bovine dialyzable lymph node extracts on human cell-mediated immunity. In: Immune Regulators in Transfer Factor (A. Khan, C.H. Kirkpatrick and N.O. Hill, eds.) Academic Press, pp. 161-177, 1979.
33. G.B. Wilson, H.T. Johnson, Jr., P.V. Halushka, B.P. Garner, M.N. Berkaw, R.E. Powers, and H.H. Fudenberg. Contribution of prostaglandins to the antigen independent biological activity of dialyzable leukocyte extracts containing transfer factor activity. In: Immune Regulators in Transfer Factor (A. Khan, C.H. Kirkpatrick and N.O. Hill, eds.) Academic Press, pp. 137-147, 1979.
34. G.V. Paddock, G.B. Wilson, H.H. Fudenberg, A.C. Wang, and R.E. Lovins. Purification and structural analysis of the transfer factor-like activity detected in vitro by leukocyte migration inhibition. In: Immune Regulators in Transfer Factor (A. Khan, C.H. Kirkpatrick and N.O. Hill, eds.) Academic Press, pp. 419-431, 1979.
35. G.B. Wilson, L. Johnson, C.L. Smith, and H.H. Fudenberg. Possible identification of an antigen-independent leukocyte migration inhibitory activity in human dialyzable leukocyte extracts as neutrophil immobilizing factor. In: Immune Regulators in Transfer Factor (A. Khan, C.H. Kirkpatrick and N.O. Hill, eds.) Academic Press, pp. 191-204, 1979.
36. G.B. Wilson, R.T. Newell, and N.M. Burdash. Bovine dialyzable lymph node extracts have antigen-dependent and antigen-independent effects on human cell mediated immunity in vitro. Cell. Immunol. 47: 1-18, 1979.
37. G.B. Wilson, C.L. Smith, and H.H. Fudenberg. Effects of dialyzable leukocyte extracts (DLE) with transfer factor activity on leukocyte migration in vitro. III. Characterization of the antigen-independent migration inhibition factor in DLE as a neutrophil immobilizing factor. J. Allerg. Clin. Immunol. 64: 56-66, 1979.



- (38.) R.T. Newell, G.B. Wilson, N.M. Burdash, and H.H. Fudenberg. In vitro stimulation of human T-cell rosette formation by bovine lymph node extracts. J. Clin. Immunol. 64: 56-66, 1979.
- (39.) G.V. Paddock, G.B. Wilson, and A.C. Wang. Contribution of hydrolyzed nucleic acids and their constituents to the apparent amino acid composition of biological compounds. Biochem. Biophys. Res. Comm. 87: 946-952, 1979.
40. G.B. Wilson. Cystic fibrosis protein is a confirmed diagnostic marker for detecting heterozygote carriers. Significance in relation to future screening and to a proposed defect in alpha2-macroglobulin. Pediat. Res. 13: 1079-1081, 1979.
- (41.) G.B. Wilson, H.H. Fudenberg, and G.V. Paddock. Detection of "dialyzable transfer factor" in vitro: Structural and chemical characterization of the activity specific for tuberculin. Ann. N.Y. Acad. Sci. 332: 579-590, 1979.
- (42.) G.B. Wilson, G.V. Paddock, and H.H. Fudenberg. The chemical nature of the antigen-specific moiety of transfer factor. Trans. Assoc. Amer. Phys. 92: 239-256, 1979.
- (43.) C.U. Kyong, G.B. Wilson, H.H. Fudenberg, J.M. Goust, P. Richardson, and J. Echerd. Chorioretinitis with a combined defect in T and B lymphocytes and granulocytes: A new syndrome successfully treated with dialyzable leukocyte extracts (transfer factor). Amer. J. Med. 68: 955-961, 1980.
- (44.) G.B. Wilson, H.H. Fudenberg, H.T. Johnson, Jr., and C.L. Smith. Effects of dialyzable leukocyte extracts with transfer factor activity on leukocyte migration in vitro. IV. Two distinct effects of DLE on leukocyte migration can be produced by prostaglandins. Clin. Immunol. Immunopathol. 16: 90-102, 1980.
45. G.B. Wilson, J.H. Walker Jr., J.H. Watkins Jr., and D. Wolgroch. Determination of subpopulations of leukocytes involved in the synthesis of alpha<sub>1</sub>-antitrypsin in vitro. Proc. Soc. Exp. Biol. Med. 164: 105-114, 1980.
46. G.B. Wilson and V.J. Bahm. Synthesis and secretion of cystic fibrosis ciliary dyskinesia substances by purified subpopulations of leukocytes in vitro. J. Clin. Invest. 66: 1010-1019, 1980.
47. G.B. Wilson. Development of monospecific antisera, hybridoma antibodies, and immunoassays for cystic fibrosis protein. Lancet ii: 313-314, 1980.
- (48.) G.B. Wilson, G.V. Paddock, and H.H. Fudenberg. Effects of dialyzable leukocyte extracts with transfer factor activity on leukocyte migration in vitro. V. Antigen-specific lymphocyte responsiveness can be initiated by two structurally distinct polyribonucleopeptides. Thymus 2: 257-276, 1981.

- (47.) J.F. Metcalf, J.F. John, G.B. Wilson, H.H. Fudenberg, and R.A. Harley. *Mycobacterium fortuitum* pulmonary infection associated with an antigen selective defect in cell-mediated immunity. Amer. J. Med. 71:485-492, 1981.
50. G.B. Wilson, H.H. Fudenberg, M.T. Parise, and E. Floyd. Cystic fibrosis ciliary dyskinesia substances (CDS) and pulmonary disease: Effects of CDS on neutrophil movement in vitro. J. Clin. Invest. 68: 171-183, 1981.
51. G.B. Wilson and E. Floyd. Detection and characterization of cystic fibrosis protein employing isoelectric focusing and immunoelectrophoretic techniques. In: Electrophoresis '81 (R.C. Allen and P. Arnaud, eds.), pp. 529-535, 1981.
- (52.) G.V. Paddock, G.B. Wilson, F.K. Lin, N. O'Leary and H.H. Fudenberg. Effects of dialyzable leukocyte extracts with transfer factor activity on leukocyte migration in vitro. VI. Studies on the primary structure of transfer factor. In: Electrophoresis '81 (R.C. Allen and P. Arnaud, eds.), pp. 479-485, 1981.
53. G.B. Wilson. Cystic Fibrosis: Immunoassays for carrier detection and metabolic correction in vitro. In: Clinical Genetics: Problems in Diagnosis and Counselling (A.M. Willey, T. P. Carter, S. Kelly and I.H. Porter, eds.), Academic Press, pp. 215-256, 1982.
54. G.B. Wilson and H.D. Jackson. Cystic Fibrosis: Further characterization of a "new" cytokine which modulates neutrophil and monocyte chemotaxis. In: Human Lymphokines: Biological Immune Response Modifiers (A. Khan and N. O. Hill, eds.), Academic Press, pp. 605-620, 1982.
55. G.B. Wilson and H.H. Fudenberg. Does a host defense abnormality involving monocytes-macrophages underlie the pathogenesis of lung disease in cystic fibrosis? Medical Hypotheses 8: 527-542, 1982.
- (56.) G.B. Wilson, J.F. Metcalf and H.H. Fudenberg. Treatment of Mycobacterium fortuitum pulmonary infection with "transfer factor" (TF): New methodology for evaluating TF potency and predicting clinical response. Clin. Immunol. Immunopathol. 23:478-491, 1982.
- (57.) G.B. Wilson, G.V. Paddock and H.H. Fudenberg. Bovine "transfer factor": An oligoribonucleopeptide which initiates antigen-specific lymphocyte responsiveness. Thymus, 4: 335-350, 1982.
58. G.B. Wilson, J.F. Metcalf, E. Floyd, J.E. Smalls, C.J. Pickett, and H.H. Fudenberg. Differential immunomodulatory effects of antibiotics on cellular immune reactivity: An indicator of potential antibiotic toxicity. Ann. N.Y. Acad. Sci., 407: 432-435, 1983.



57. G.V. Paddock, G.B. Wilson, A.M. Williams, and H.H. Fudenberg. Human transfer factor: Exogenous labelling, purification, and role of ribonucleic acid segment. In: Immunobiology of Transfer Factor (C.H. Kirkpatrick, H.S. Lawrence, and D.R. Burger, eds.), Academic Press, pp. 51-62, 1983.
60. H.H. Fudenberg, G.B. Wilson, R.H. Keller, J.F. Metcalf, E.E. Paull, E.J. Stuart, and E. Floyd. Clinical applications of the leukocyte migration inhibition assay - New methods for determining transfer factor potency and for predicting clinical response. In: Immunobiology of Transfer Factor (C.H. Kirkpatrick, H.S. Lawrence, and D.R. Burger, eds.), Academic Press, pp. 293-309, 1983.
61. K.Y. Tsang, H.H. Fudenberg, and G.B. Wilson. Osteosarcoma-specific dialyzable extracts: Prophylaxis post-surgery in an animal model of human osteosarcoma. In: Immunobiology of Transfer Factor (C.H. Kirkpatrick, H.S. Lawrence, and D.R. Burger, eds.), Academic Press, pp. 157-173, 1983.
62. G.B. Wilson, M.L. Morin, L.D. Stuart, A.M. Williams, E. Floyd, G.V. Paddock, L. Just, and H.H. Fudenberg. Transfer of cell-mediated immunity in vitro to human lymphocytes using dialyzable leukocyte extracts from immune Burros. In: Immunobiology of Transfer Factor (C.H. Kirkpatrick, H.S. Lawrence, and D.R. Burger, eds.), Academic Press, pp. 213-229, 1983.
63. G.B. Wilson, G.V. Paddock, E. Floyd, R.T. Newell, and M.H. Dopson. Immunochemical and physical-chemical evidence for the presence of thymosin alpha<sub>1</sub>-peptide in dialyzable leukocyte extracts. In: Immunobiology of Transfer Factor (C.H. Kirkpatrick, H.S. Lawrence, and D.R. Burger, eds.), Academic Press, pp. 392-410, 1983.
64. G.B. Wilson, H.H. Fudenberg, G.V. Paddock, K.Y. Tsang, A.M. Williams, and E. Floyd. Mechanism(s) of action of human transfer factor: Insights obtained from studying "antigen liberated transfer factor" specific for tuberculin. In: Immunobiology of Transfer Factor (C.H. Kirkpatrick, H.S. Lawrence, and D.R. Burger, eds.), Academic Press, pp. 331-346, 1983.
65. G.B. Wilson and E. Floyd. Cystic Fibrosis: "Normalization" of monocyte-macrophage metabolism depends on the form of alpha<sub>2</sub>-macroglobulin. Ann. N.Y. Acad. Sci. 421: 404-409, 1983.
66. G.B. Wilson, H.H. Fudenberg, and R.H. Keller. Guidelines for immunotherapy of antigen-specific defects with transfer factor. J. Clin. Lab. Immunol., 13: 51-58, 1984.
67. D.B. Vasily, F. Miller, H.H. Fudenberg, J.M. Goust, and G.B. Wilson. Epidermodysplasia verruciformis: Response to therapy with dialyzable leukocyte extract (transfer factor) derived from household contacts. J. Clin. Lab. Immunol., 14: 49-57, 1984.

68. G.B. Wilson, G.V. Paddock, E. Floyd, R.T. Newell, and M.H. Dopson. Dialysable leukocyte extracts contain thymosin. Thymus, 6: 167-180, 1984.
69. G.B. Wilson, J. McIntosh, J. Dietrich, and T. Manning. Controlled comparison of plasma and serum for cystic fibrosis protein. Clin. Genetics, 26: 331-338, 1984.
70. J.F. Metcalf and G.B. Wilson. Use of mitogen-induced lymphocyte transformation to assess toxicity of aminoglycosides. J. Environmental Pathol. Toxicol. Oncol., 7: 27-37, 1987.
71. G.B. Wilson, C. Poindexter, J.D. Fort, and K.D. Ludden. Specific pathogen free and standard commercial chickens as models for evaluating xenogenic transfers of cell-mediated immunity. In: Leukocyte Dialysates and Transfer Factor (V. Mayer and J. Borvak, eds.), Institute of Virology, Slovak Academy of Sciences, Bratislava, Czechoslovakia, pp. 257-274, 1987.
72. G.B. Wilson and J.D. Fort. Interspecies transfers of cell-mediated immunity using specific immunity inducers with known potency-prevention in selected diseases. In: Leukocyte Dialysates and Transfer Factor: (V. Mayer and J. Borvak, eds.), Institute of Virology, Slovak Academy of Sciences, Bratislava, Czechoslovakia, pp. 333-358, 1987.
73. G.B. Wilson, C. Poindexter, J.D. Fort, and K.D. Ludden. De novo initiation of specific cell-mediated immune responsiveness in chickens by transfer factor (Specific Immunity Inducer) obtained from bovine colostrum and milk. Acta Virologica, 32: 6-18, 1988.
74. G.S. Appleton and G.B. Wilson. Immunomodulators: Getting the first product to market. In: AqBiotech '88, Conference Management Corporation, Norwalk, Connecticut, pp. 65-77, 1988.
75. G.B. Wilson and R. Riley-Shuler. Swine Transmissible Gastroenteritis Specific Immunity Inducer (Transfer Factor): Clinical Efficacy and Licensing by the United States Department of Agriculture. In: Research and Application of Transfer Factor (H. Bao-Lai, W. Ru-Zhang, Z. Zhao-Fen, eds.), XueYuan Press, Beijing, pp. 259-277, 1989.
76. G.V. Paddock, M.F. Thomas, P.G. Germroth and G.B. Wilson. Structural Comparisons of Avian and Mammalian Transfer Factor. In: Research and Application of Transfer Factor (H. Bao-Lai, W. Ru-Zhang, Z. Zhao-Fen, eds.), XueYuan Press, Beijing, pp. 95-116, 1989.

## REVIEWS

1. H.H. Fudenberg, J.M. Goust, M.P. Arala-Chaves, and G.B. Wilson. Dialyzable transfer factor: An analytical review. Folia Allergol. Immunol. Clin. 23 (1): 1-23, 1976.
2. H.H. Fudenberg and G.B. Wilson. Dialyzable transfer factor: Clinical uses and studies on purification of the activity. In: Current Topics in Clinical Chemistry Vol. 3 Clinical Immunochemistry, Chemical and Cellular Basis and Application in Disease (S. Natelson, A.J. Pesce, A.A. Dietz, eds.), American Association for Clinical Chemistry, Washington, D.C. pp. 228-250, 1978.
3. H.H. Fudenberg, G.B. Wilson, J.M. Goust, K. Nekom, and C.L. Smith. Dialyzable leukocyte extracts (transfer factor): A review of clinical results and immunological methods for donor selection, evaluation of activities, and patient monitoring. In: Thymus, Thymic Hormones and T Lymphocytes (F. Aiuti and H. Wigzell, eds.), Academic Press, London, pp. 391-421, 1980.
4. H.H. Fudenberg, G.B. Wilson, and C.L. Smith. Immunotherapy with dialyzable extracts and studies of their antigen-specific (Transfer Factor) activity. Proc. Virchow Pirquet Med. Soc., 34: 3-87, 1980.
5. G.B. Wilson, and H.H. Fudenberg. Leukocyte migration inhibition as a method for assaying transfer factor activities. Lymphokines 4: 107-173, 1981.
6. G.B. Wilson and H.H. Fudenberg. Is the controversy about "transfer factor therapy" nearing an end? Immunology Today, 4: 157-161, 1983.
7. G.B. Wilson, Ciliary dyskinesia factors produced by leukocytes. Lymphokines 8: 323-372, 1983.
8. E. Shapira and G.B. Wilson. Introduction - An overview of cystic fibrosis. In: Immunological Aspects of Cystic Fibrosis (E. Shapira and G.B. Wilson, eds.), CRC Press Inc., Boca Raton, Florida, pp. 1-4, 1984.
9. G.B. Wilson. Cell-mediated immunity in cystic fibrosis. In: Immunological Aspects of Cystic Fibrosis (E. Shapira and G.B. Wilson, eds.), CRC Press Inc., Boca Raton, Florida, pp. 57-78, 1984.
10. G.B. Wilson. Cystic fibrosis factors: their involvement in immunity and the pathogenesis of cystic fibrosis. In: Immunological Aspects of Cystic Fibrosis (E. Shapira and G.B. Wilson, eds.), CRC Press Inc., Boca Raton, Florida, pp. 149-197, 1984.

- (11.) H.H. Fudenberg, G.B. Wilson, and K.Y. Tsang. Evaluation of potency and predictability of clinical response to DLE containing transfer factor. In: Immunomodulation and Thermootherapy in Cancer (H.H. Fudenberg, P. Potiggia and C. Ogier, eds.), Acta Medica Press, Italy, pp. 141-151, 1983.
- (12.) H.H. Fudenberg, G.B. Wilson and K.Y. Tsang. Evaluation of transfer factor: Potency and prediction of clinical response. In: Immunomodulation: New Frontiers and Advances (H.H. Fudenberg, H.D. Whitten, and F. Ambrogio, eds.), Plenum Press, Inc., N.Y., pp. 115-130, 1984.
- (13.) G.B. Wilson and J.B. Daily, Jr. Transfer Factors and Immunity. Healthy and Natural Journal 6: 72-73, 1999.

BOOKS

1. E. Shapira and G.B. Wilson (eds.). Immunological Aspects of Cystic Fibrosis. CRC Press Inc., Boca Ration, Florida, 1984.
-



# Positive Health News

**Report No 17**

**Fall Issue (1998)**

*An extract from Elder berries, used in combination with a common treatment for Arthritis (glucosamine and chondroitin sulfate), inhibits HIV and other lipid envelope viruses.*

**Editor's Message on AIDS and CFIDS - Where is the Cure?**

**Transfer Factor specific for HHV-6A now under development**

**Sulfated polysaccharides (glucosamine & chondroitin sulfate) inhibit HIV and other viruses**

**Elder Berries - anti-viral and metabolic effects**

**Interviews and Anecdotal reports**

**Hepatitis C - Promising new treatments - transfer factor panel for A, B and C and Thy-Mates.**

**L-Glutamine increases Glutathione levels & heals mucosal membranes**

**Hybrid - Protocols - an idea whose time has come**

**Protease inhibitors - problems with lipid metabolism may preclude long term use.**

**Inositol hexaphosphate (IP6) - a natural substance found in brown rice and whole kernel corn stimulates natural killer cell activity**

**Essential oils of peppermint, orange & lemongrass inhibit most strains of fungal and bacterial infections**

**BEST AVAILABLE COPY**

Applicants: Gregory B. Wilson et al.  
U.S. Serial No.: 09/776,010

## **"IMMUNFACTOR"** **Supports Immune Function**

**IMMUNFACTOR 1:** Contains antigen-specific transfer factors (TF) against HIV, pneumocystis carinii, mycobacterium avian, human tuberculosis, bovine tuberculosis, herpes 1, herpes 2, HHV6, EBV, CMV, candida albicans, and cryptosporosis. Supports immune function for persons affected by HIV.

**IMMUNFACTOR 2:** Contains antigen-specific transfer factors against EBV, CMV, herpes 1, herpes 2, candida pneumoniae, mycoplasma, lyme, and candida albicans. Supports immune function for persons affected by Chronic Fatigue Syndrome.

**IMMUNFACTOR 3:** Contains antigen-specific transfer factors against hepatitis A, B, and C. Supports immune function for persons affected by hepatitis A, B, and C.

**IMMUNFACTOR 4:** Contains antigen-specific transfer factors against childhood illnesses, flu, and viruses. Supports immune for persons affected with these disease states.

**IMMUNFACTOR 5:** Contains antigen-specific transfer factors against microbial entities. Supports immune function and increases natural killer cell activities for persons who are immune compromised.

All ImmunFactors are available in:

P: 100 mg gel capsules (20-mg antigen-specific TF, 80-mg beta glucan), 40 capsules per bottle

DS: 100-mg gel capsules (33-mg antigen-specific TF), 30 capsules per bottle

T: 100-mg gel capsules (67-mg antigen-specific TF), 90 capsules per bottle

**THYMBURSYN:** Through recent technological advances and mechanical extraction methods, this formulation contains biologically complete and active thymus (supports cell-mediated immunity) and bursa (supports humoral immunity) factors. The thymuses are collected from 8-12-week-old rabbits that have been raised organically and the bursas are collected from 8-10-week-old chickens. Thymbursyn contains as many as 18 biologically active moieties as suggested in the peer-reviewed literature that work synergistically. Thymbursyn supports the immune function.

**BETAMAX:** Beta 1,3 D glucan now improved and more highly purified with removal of fatty acids to increase purity, palatability, and quality. An important supplement that supports macrophage and neutrophil function.

BetaMax100: 100-mg gel capsules, 60 capsules per bottle

BetaMax425: 425-mg gel capsules, 60 capsules per bottle

BetaMax500: 500-mg gel capsules, 60 capsules per bottle

BetaMax: 250 grams bulk powder, 500 grams bulk powder,  
1000 grams bulk powder.

### **PRODUCTS IN PROGRESS:**

**IMMUNFACTOR6:** HHV6 STRAINS A AND B - contains transfer factors specific for various subsets.

**ImmunoSaccharides:** A highly active blend of polysaccharides encompassing glucans, mushroom glucans, and mucopolysaccharides. ImmunFactor technology is employed to nutritionally support and activate natural killer cell function. ImmunoSaccharides contains mixed polysaccharides that support and activate many different subclasses of immunocytes more effectively than a single source polysaccharide. Available in 1999.

1 800 664-1333

1 803 663-9618

1 803 663-6019

Pricing and Order Line Only

Call for Technical Assistance

Fax Line

biolab@mindpsring.com

Email

http://www.immumdynamics.com

Web site

CHISOLM BIOLOGICAL LABORATORY

BEST AVAILABLE COPY



# Positive Health News

Report No 15

Fall Issue (1997)

- ◆ A Personal Message from the Editor
- ◆ An Open Letter to Dr. Anthony Fauci MD (NIAID) calls for NIH/NIAID trials on immune-based therapies
- ◆ Restoring Natural Killer Cell Function with NK911 with a report on Biotic Code 614 by Jesse Stoff MD
- ◆ Need to talk to someone using immune-based therapies?
- ◆ HHV-6A may impair antigen presentation
- ◆ Three important immune function diagnostic tests
- ◆ Monthly Voice Mail Message updates
- ◆ To AIDS and back - Marc Correa's protocol
- ◆ Letters from Ugandan AIDS patients appeal for help
- ◆ Low Dose Naltrexone in the treatment of autoimmune disease, by Dr. Bernard Bihari MD
- ◆ Candida Albicans promote a shift in CD4 cytokine production from TH1 to TH2

BEST AVAILABLE COPY

Applicants: Gregory B. Wilson et al.  
U.S. Serial No.: 09/776.010



## ImmunFactor™

... is our trademark for Transfer Factors, previously marketed by AJ Lanigan, formerly an agent for our biotechnology company, Chisolm Biological Laboratories. We are no longer using marketing agents but have chosen direct sales through distributors.

... is the only Transfer Factor directed against HIV; herpes 1; herpes 2; candida albicans; pneumocystic carinii; bovine tuberculosis; human tuberculosis; Epstein Barr virus; cytomegalovirus; mycobacterium avian; HHV6; and cryptosporosis!!!

Do not be fooled by simple dried colostrum/whey products (already been marketed for years) which elicit a nonspecific immune response (demonstrated by elevated NK activity). Now these products are labeled as Transfer Factors, which are manufactured by unknown MDs and PhDs with purported years of experience and no scientific publications. Only ImmunFactor™ (specifically identifying) has defense against the above antigens which do not naturally occur in colostrum/whey products. We feel specificity (Transfer Factor's true function) is the KEY to treatment. Will nonspecific modulation lower PCR and raise T cell counts? ImmunFactor™ has demonstrated this in clinical tests. During the past twenty years, our experience in academia has involved one of the top Transfer Factor research teams in the world who authored 587 of 3000+ peer-reviewed publications and acquired clinical data worldwide. TF production is more similar to art than science. Rely on bona fide experience and products that have proven results accompanied with clinical data.

Products in progress: (1) Generic (cost effective) NK-911 with additional components of NK activating effects; (2) ImmunFactor™ against hepatitis A, B, and C; (3) Thymic Factors (from organically raised rabbits); (4) Thymic/Bursa Factors; (5) *Saccharomyces boulardii* yeast with Transfer Factors directed against *Clostridium difficile* which causes diarrhea; (6) Regenerative Enzyme made from lactobacillus. This product includes soil microbes and all the friendly bacteria missing in our food chain due to the overprocessing of our foods.

⇒ Look for our Beta Glucans (BetaMax™) now discounted below the retail prices to make it even more affordable for those in need.

⇒ Inquire how to receive a free bottle of BetaMax™ 425 (Beta 1,3 D-Glucan) on your next ImmunFactor™ order (limited time offer).

Visit our web site at [www.immumdynamics.com](http://www.immumdynamics.com) or call 1-800-664-1333 for distributors in your area.

# "ROEX OLEUROPEIN"

## OLIVE LEAF EXTRACT

THE HIGHEST QUALITY OLEUROPEIN PRESENTLY AVAILABLE!

- ANTI-VIRAL
- ANTI-RETROVIRAL
- ANTI-BACTERIAL
- ANTI-FUNGAL
- ANTI-PARASITIC
- ANTI-INFLAMMATORY



- IMMUNE STIMULATORY
- NATURAL ENERGY BOOSTER
- NORMALIZES SERUM CHOLESTEROL
- NORMALIZES BLOOD PRESSURE

\*A NEW "PHYTOTHERAPY" FOR HIV, HERPES & OTHER VIRAL DISEASES!

\*A POWERFUL NEW WEAPON AGAINST VIRUSES & BACTERIA!

ROEX, INC. ■ SUITE # 185 ■ 2081 BUSINESS CENTER DRIVE ■ IRVINE, CALIFORNIA 92612

TOLL FREE: (800) 645-0010 ■ FAX: (714) 476-8682 ■ WEB SITE: <http://roex.com>

BEST AVAILABLE COPY